TrialNature medicine2022

Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial.

Tomoki Todo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.